40-Gene Expression Profile for Cutaneous Squamous Cell Carcinoma Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the risk of recurrence and metastasis in cutaneous squamous cell carcinoma (cSCC) are inadequate, as they fail to accurately identify patients at high risk, leading to overtreatment of low-risk patients and missed recurrences in high-risk individuals, with existing clinical and pathologic features collectively failing to identify 30-40% of recurrences and high-risk features not always correlating with metastasis.
Innovation Solution
A 40-gene expression profile (40-GEP) test is developed, which determines the expression levels of 34 specific genes in a tumor sample to generate a probability score for metastasis risk, categorizing patients into low, moderate, or high risk classes, and is used in conjunction with clinical and pathologic factors for improved risk stratification and treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical and pathologic features are used to predict recurrence risk, then treatment decisions can be made based on available data, but 30-40% of recurrences are not identified and many high-risk features do not correlate with actual metastasis
Solution Approach 1:
The patent transitions from using traditional clinical and pathologic parameters to measuring gene expression levels as a new parameter set. This involves quantifying the expression levels of specific genes (e.g., through RT-PCR or microarray analysis) and using these molecular parameters to predict recurrence risk, thereby achieving higher accuracy than morphological features alone
Solution Approach 2:
The patent introduces a molecular signature or gene expression profile as an intermediary between the tumor tissue and the prediction of recurrence. This intermediary provides objective molecular data that bridges the gap between observable clinical features and actual metastatic potential, enabling more accurate risk stratification
2Reliability
If aggressive treatment is administered to all patients with high-risk features, then potential recurrences may be prevented, but overtreatment occurs in patients with low actual risk
Solution Approach 1:
The patent applies local quality by differentiating treatment strategies based on individual patient risk profiles determined by gene expression patterns. Instead of uniform aggressive treatment, patients are stratified into risk categories (e.g., high, intermediate, low) and receive tailored interventions, applying aggressive treatment only to those with truly high molecular risk while sparing low-risk patients from unnecessary side effects
Solution Approach 2:
The patent enables partial action by allowing clinicians to apply aggressive treatment selectively rather than universally. By using gene expression data to identify only the subset of patients who truly benefit from intensive therapy, the approach applies treatment intensity proportional to actual risk, avoiding excessive action in low-risk individuals
3Measurement precision
If molecular analysis is implemented to improve prediction accuracy, then risk stratification improves, but test complexity and cost increase
Solution Approach 1:
The patent extracts specific molecular markers or gene signatures from the complex genomic landscape to create a focused, clinically actionable test panel. By selecting and analyzing only the most relevant genes associated with recurrence (rather than performing comprehensive genomic sequencing), the approach reduces test complexity while maintaining high predictive accuracy
Solution Approach 2:
The patent segments the complex problem of cancer recurrence prediction into discrete, measurable gene expression components. By dividing the assessment into specific gene targets that can be measured independently and then integrated into an overall risk score, the system makes the complex molecular analysis manageable and clinically implementable
Data Source
AI summary
The present disclosure relates to methods for predicting the risk of recurrence and/or metastasis, or both in primary cutaneous squamous cell carcinoma (cSCC).